Letters in Drug Design & Discovery

Papers
(The H4-Index of Letters in Drug Design & Discovery is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The New Era of Drug Discovery: The Power of Computer-aided Drug Design (CADD)42
Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery39
In Silico Identification of New Anti-SARS-CoV-2 Agents from Bioactive Phytocompounds Targeting the Viral Spike Glycoprotein and Human TLR422
Phytoestrogens as Potential Antiandrogenic Agents Against Prostate Cancer: An In Silico Analysis22
Combinatorics, Big Data, Neural Network & AI for Medicinal Chemistry & Drug Administration21
Survey on Medicinal Plants and Herbs in Traditional Iranian Medicine with Anti-oxidant, Anti-viral, Anti-microbial, and Anti-inflammation Properties21
Synthesis and Anticancer Activities of Novel Bis-chalcones Incorporating the 1,3-diphenyl-1H-pyrazole Moiety: In Silico and In Vitro Studies20
Synthesis, Antimicrobial Activity, and Molecular Modeling Studies of Some Benzoxazole Derivatives19
Molecular Docking Analysis of Flavonoid Compounds with Matrix Metalloproteinase- 8 for the Identification of Potential Effective Inhibitors18
Chalcones and Bis-Chalcones Analogs as DPPH and ABTS Radical Scavengers16
Design, Synthesis, and In Silico Studies of Novel N-(2-Aminophenyl)-2,3- Diphenylquinoxaline-6-Sulfonamide Derivatives Targeting Receptor- Binding Domain (RBD) of SARS-CoV-2 Spike Glycoprotein and the15
Recent Advances in Drug Design and Delivery Across Biological Barriers Using Computational Models14
In-silico Study to Identify Dietary Molecules as Potential SARS-CoV-2 Agents13
Repurposing FDA-approved Drugs Targeting SARS-CoV2 3CLpro: A Study by Applying Virtual Screening, Molecular Dynamics, MM-PBSA Calculations and Covalent Docking13
0.065684080123901